A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Brief description of study

The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers. We want to find out what effects, good or bad, the study drug has on you and your cancer. This is an investigational study of a drug named MRTX849, which means it is still being tested and is not approved by the US Food and Drug Administration (FDA) as a routine therapy. This study is the first time that patients will be treated with MRTX849. MRTX849 is able to shrink or slow down the growth of tumors. It is not known whether MRTX849 will do the same in patients, where the growth of tumors is more complicated. You are being asked to participate because you have a diagnosis of advanced cancer for which there are no standard therapies beyond those you have been offered and/or already received.


Clinical Study Identifier: s19-00037
ClinicalTrials.gov Identifier: NCT03785249
Principal Investigator: Joshua K Sabari.
Other Investigators: Anam Qureshi, Elaine Shum, Scot Niglio, Vamsidhar Velcheti, Eneil De La Pena, Janice Mehnert, Maya Dimitrova, Jeffrey S. Weber, Salman Rafi Punekar, Jonathan B Kahn, Keriann M Scavone, Nina Beri, Avital Benson, Caitlin Elizabeth Ryan, David R. Wise, Abraham Chachoua, Jessica Wang, Carol M Lee, Sally Lau, Samantha VanMaanen, Kristen Spencer, Gabrielle Fridman, Nancy Chan, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.